TCGA-86-8668-01A-11R-2403-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 61
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- COAGULATION+0.290
- ANGIOGENESIS+0.280
- UV_RESPONSE_DN+0.280
- KRAS_SIGNALING_UP+0.250
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.180
- HEDGEHOG_SIGNALING+0.180
- NOTCH_SIGNALING+0.180
- TGF_BETA_SIGNALING+0.160
- APICAL_JUNCTION+0.140
- BILE_ACID_METABOLISM+0.140
Top 10 suppressed
- MYC_TARGETS_V2-0.620
- MYC_TARGETS_V1-0.580
- E2F_TARGETS-0.570
- G2M_CHECKPOINT-0.550
- OXIDATIVE_PHOSPHORYLATION-0.540
- MTORC1_SIGNALING-0.460
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.430
- DNA_REPAIR-0.410
- UNFOLDED_PROTEIN_RESPONSE-0.290
- PANCREAS_BETA_CELLS-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-B6-A0IH-01A-11R-A115-07 | — | A | 0.908 |
| 2 | C3L-03268 | — | cohortA1 | 0.899 |
| 3 | TCGA-55-A57B-01A-12R-A39D-07 | — | cohortA1 | 0.892 |
| 4 | TCGA-AC-A8OS-01A-12R-A41B-07 | — | A | 0.891 |
| 5 | 895018d4-b355-4339-8c60-186478ae6551 | — | — | 0.891 |
| 6 | TCGA-G2-A2EC-01A-11R-A180-07 | — | — | 0.886 |
| 7 | 6b32f047-89ca-40e7-950f-a03493ea90c7 | — | — | 0.886 |
| 8 | TCGA-CR-6488-01A-12R-2081-07 | — | — | 0.879 |
| 9 | TCGA-97-8174-01A-11R-2287-07 | — | cohortA2 | 0.877 |
| 10 | 102d912c-5882-4ae4-9eaf-cbd2f55f66af | — | — | 0.876 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| COAGULATION | 0.290 | Binimetinib | — uncovered |
| ANGIOGENESIS | 0.280 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.280 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.250 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.180 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.180 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.180 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.160 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.140 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.140 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.130 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.090 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.080 | Idelalisib | — uncovered |
| COMPLEMENT | 0.080 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.040 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.040 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.030 | Idelalisib | — uncovered |